Myeloid Leukemia, Philadelphia-Positive

Myeloid Leukemia, Philadelphia-Positive — Trials · CancerIndex

Clinical trials

Registered studies

17 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7
Recruiting: 3
Ph III recruiting: 1
Growth YoY: —
Industry share: 43%
Top sponsor: M.D. Anderson Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03459534	A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs	recruiting	Phase 3	173	Il-Yang Pharm. Co., Ltd.INDUSTRY	4	Sep 3, 2026	clinicaltrials
NCT05456191	A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)(ASC4START)	active not recruiting	Phase 3	568	Novartis Pharmaceuticals